Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Use of the Bruininks-Oseretsky test of motor proficiency (BOT-2) to assess efficacy of velmanase alfa as enzyme therapy for alpha-mannosidosis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The impact of consanguinity on the frequency of inborn errors of metabolism

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Residual OCTN2 transporter activity, carnitine levels and symptoms correlate in patients with primary carnitine deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. When should social service referral be considered in phenylketonuria?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Treatment of monogenic disorders with viral transduced haematopoietic stem cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The SPARKLE registry: protocol for an international prospective cohort study in patients with alpha-mannosidosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Genotype-phenotype associations in PPGLs in 59 patients with variants in SDHX genes

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Dawn Phillips
  • Julia B Hennermann
  • Anna Tylki-Szymanska
  • Line Borgwardt
  • Mercedes Gil-Campos
  • Nathalie Guffon
  • Yasmina Amraoui
  • Silvia Geraci
  • Diego Ardigò
  • Federica Cattaneo
  • Allan M Lund
View graph of relations

Objectives: Alpha-mannosidosis is a rare autosomal recessive lysosomal storage disorder resulting from deficient lysosomal alpha-mannosidase activity. Clinical manifestations include progressive balance disorders, immune deficiency, skeletal abnormalities and cognitive deficits beginning in early childhood. Enzyme replacement therapy with recombinant human alpha-mannosidase (velmanase alfa) is scheduled for clinical development in the US beginning in 2020 and has been approved in the EU for treatment of non-neurological manifestations in cases of mild to moderate disease. This study assessed effects of velmanase alfa on fine and gross motor proficiency in children and adults.

Methods: Integrated Bruininks-Oseretsky (BOT-2) test of Motor Proficiency data from velmanase alfa clinical trials was stratified by age for 14 adults and 19 children treated for up to 4 years.

Results: Patients showed global developmental delays at baseline. For the combined adult and pediatric group there was a statistically significant increase (improvement) in BOT-2 total point score of 13% (p = .035, 95% CI 1.0, 25.0) from baseline to last observation. When stratified by pediatric versus adult patients, there was improvement in BOT-2 total point score in patients <18 years (mean percent increase from baseline to last observation 23%) compared to adults (mean decrease of -0.7%). Subtest analysis of individual BOT-2 items captured some improvement following velmanase alfa treatment in pediatric patients.

Conclusions: There was limited ability to assess the BOT-2 change responses in adults. Pediatric patients showed stability or improvement in scaled scores relative to healthy peers, indicating continued skill acquisition, which may increase independence and contribute to improved patient quality of life.

Original languageEnglish
JournalMolecular Genetics and Metabolism Reports
Volume23
Pages (from-to)100586
ISSN2214-4269
DOIs
Publication statusPublished - Jun 2020

ID: 62074560